Foster vs Seretide in COPD - FUTURE Study

• Research type

  Research Study

• Full title

  A 12-week, multicentre, multinational, randomized, double-blind, double-dummy, 2-arm parallel group study comparing the efficacy and safety of Foster® 100/6 (beclomethasone dipropionate 100 µg plus formoterol 6 µg/actuation), 2 puffs b.i.d., versus Seretide® 500/50 (fluticasone 500 µg plus salmeterol 50 µg/actuation), 1 inhalation b.i.d., in patients with Chronic Obstructive Pulmonary Disease.

• IRAS ID

  68801

• Contact name

  Dave Singh

• Contact email

  dsingh@meu.org.uk

• Sponsor organisation

  Chiesi Farmaceutici S.p.A.

• Eudract number

  2009-014410-10

• ISRCTN Number

  0

• Clinicaltrials.gov Identifier

  0

• Research summary

  The purpose of the present study is to determine the effects on health status and spirometric values of Foster© 100/6 (two puffs b.i.d.) versus Seretide© 500/50 (one inhalation b.i.d.), over a 12-week treatment period in COPD patients.

• REC name

  North West - Haydock Research Ethics Committee

• REC reference

  11/NW/0019

• Date of REC Opinion

  22 Mar 2011

• REC opinion

  Further Information Favourable Opinion